Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tiagabine
Drug ID BADD_D02210
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indications and Usage For the treatment of partial seizures
Marketing Status approved; investigational
ATC Code N03AG06
DrugBank ID DB00906
KEGG ID D08588
MeSH ID D000078308
PubChem ID 60648
TTD Drug ID D0ED7U
NDC Product Code 69238-1104; 69238-1106; 69238-1105; 69238-1107
UNII Z80I64HMNP
Synonyms Tiagabine | N-(4,4-di(3-Methylthien-2-yl)but-3-enyl)nipecotic acid | Gabitril | NO 329 | NO-329 | Tiagabine Hydrochloride | (R)-(4,4-bis(3-Methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, Hydrochloride | Tiagabine, (S)-isomer | NO 328 | NO-328
Chemical Information
Molecular Formula C20H25NO2S2
CAS Registry Number 115103-54-3
SMILES CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pelvic pain20.02.03.007; 07.01.06.012; 21.10.01.001--
Peripheral vascular disorder24.03.01.003--Not Available
Personality disorder19.05.02.002--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pharyngitis22.07.03.004; 07.05.07.004; 11.01.13.003--
Phlebitis12.02.01.002; 24.12.03.004--
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pyelonephritis20.01.09.001; 11.01.14.002--Not Available
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash pustular23.03.10.003; 11.01.12.002--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal failure20.01.03.005--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Salpingitis21.14.03.001; 11.01.10.001--Not Available
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Smear cervix abnormal13.20.02.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene